GlassScriptPhysician profile
Leanet Gonzalez
NPI 1306680145
$647.38
in general payments reported to CMS, 2019-2025
13 companies · $633 in 2025
The $633 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $14.85 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $126.75 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $93.41 | 2025 | |
| Amgen INC. | $93.36 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $87.72 | 2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Seqirus USA INC | $36.45 | 2025 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2025 | Zoryve |
| Novo Nordisk INC | $32.50 | 2025 | Ozempic |
| Ardelyx, INC. | $28.60 | 2025 | Ibsrela |
| Lilly USA, LLC | $27.29 | 2025 | Zepbound, Mounjaro |
| Saluda Medical Americas, INC. | $24.27 | 2025 | Evoke |
| Astellas Pharma US INC | $22.54 | 2025 | Veozah |
| Ars Pharmaceuticals Operations, INC. | $20.26 | 2025 | Neffy |
| Pfizer INC. | $18.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanet Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.